Trial Profile

Phase 2 proof-of-concept clinical study of OSM-0205

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OSM-0205 (Primary)
Indications Peripheral neuropathies
Focus Proof of concept; Therapeutic Use

Most Recent Events

04 Mar 2024 According to a Osmol Therapeutics media release, company plans to initiate clinical program in mid-2024.
18 Apr 2022 New trial record
12 Apr 2022 According to a Osmol Therapeutics media release, the company expect to initiate this trial mid-2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com